Marcus Mall

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4338372/publications.pdf

Version: 2024-02-01

251 papers	17,638 citations	20036 63 h-index	21239 119 g-index
270 all docs	270 docs citations	270 times ranked	17694 citing authors

#	Article	IF	Citations
1	Fibroblast Activation Proteinâ€“Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study. Journal of Nuclear Medicine, 2022, 63, 127-133.	2.8	72
2	Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study. European Respiratory Journal, 2022, 59, 2100746.	3.1	5
3	Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nature Biotechnology, 2022, 40, 319-324.	9.4	229
4	ILâ€37 regulates allergic inflammation by counterbalancing proâ€inflammatory ILâ€1 and ILâ€33. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 856-869.	2.7	25
5	Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids. Journal of Cystic Fibrosis, 2022, 21, 246-253.	0.3	24
6	Final results of the southwest German pilot study on cystic fibrosis newborn screening â€“ Evaluation of an IRT/PAP protocol with IRT-dependent safety net. Journal of Cystic Fibrosis, 2022, 21, 422-433.	0.3	8
7	Impact of lockdown during the COVID-19 pandemic on health status in patients with cystic fibrosis: a mono-centre observational study. ERJ Open Research, 2022, 8, 00588-2021.	1.1	6
8	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 2022, 185, 493-512.e25.	13.5	122
9	A Retrospective Outbreak Investigation of a COVID-19 Case Cluster in a Berlin Kindergarten, November 2020. International Journal of Environmental Research and Public Health, 2022, 19, 36.	1.2	2
10	Age-Related Differences in Structure and Function of Nasal Epithelial Cultures From Healthy Children and Elderly People. Frontiers in Immunology, 2022, 13, 822437.	2.2	5
11	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 540-549.	2.5	78
12	DMBT1 is upregulated in cystic fibrosis, affects ciliary motility, and is reduced by acetylcysteine. Molecular and Cellular Pediatrics, 2022, 9, 4.	1.0	1
13	A PI3KÎ³ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases. Science Translational Medicine, 2022, 14, eabl6328.	5.8	6
14	Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respiratory Medicine,the, 2022, 10, 267-277.	5.2	66
15	Comparison of the Lung Clearance Index in Preschool Children With Primary Ciliary Dyskinesia and Cystic Fibrosis. Chest, 2022, 162, 534-542.	0.4	11
16	Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 1053-1060.	0.3	39
17	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 311-320.	2.5	49
18	Changes in Microbiome Dominance Are Associated With Declining Lung Function and Fluctuating Inflammation in People With Cystic Fibrosis. Frontiers in Microbiology, 2022, 13, .	1.5	6

#	Article	IF	Citations
19	Normative multiple-breath washout data in school-aged children corrected for sensor error. European Respiratory Journal, 2022, 60, 2102398.	3.1	15
20	The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN. ERJ Open Research, 2022, 8, 00139-2022.	1.1	9
21	Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1361-1369.	2.5	50
22	Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+ T lymphocytes. Journal of Allergy and Clinical Immunology, 2021, 147, 753-756.	1.5	7
23	Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 381-385.	2.5	116
24	Antigenâ€driven PDâ€1 ⁺TOX⁺BHLHE40⁺ and PDâ€1 ⁺TOX⁺EOMES⁺ T lymphocytes regulate juvenile idiopathic arthritis in situ. European Journal of Immunology, 2021, 51, 915-929.	1.6	24
25	Renewed Absence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in the Day Care Context in Berlin, January 2021. Clinical Infectious Diseases, 2021, 73, 1944-1945.	2.9	4
26	CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis. Antioxidants, 2021, 10, 483.	2.2	19
27	SARS-CoV-2 in severe COVID-19 induces a TGF-Î²-dominated chronic immune response that does not target itself. Nature Communications, 2021, 12, 1961.	5.8	145
28	SARS-CoV-2 Infection, Risk Perception, Behaviour and Preventive Measures at Schools in Berlin, Germany, during the Early Post-Lockdown Phase: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2021, 18, 2739.	1.2	24
29	Therapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult Î²ENaC-Tg Mice. Mediators of Inflammation, 2021, 2021, 1-10.	1.4	3
30	Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. Thorax, 2021, 76, 1255-1265.	2.7	24
31	A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmonary Medicine, 2021, 21, 131.	0.8	17
32	Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease. International Journal of Molecular Sciences, 2021, 22, 5018.	1.8	15
33	Potential of Intestinal Current Measurement for Personalized Treatment of Patients with Cystic Fibrosis. Journal of Personalized Medicine, 2021, 11, 384.	1.1	9
34	Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis. Genes, 2021, 12, 803.	1.0	6
35	Monitoring Neutrophil Elastase and Cathepsin G Activity in Human Sputum Samples. Journal of Visualized Experiments, 2021, , .	0.2	5
36	SARS-CoV-2 infections in kindergartens and associated households at the start of the second wave in Berlin, Germanyâ€"a cross-sectional study. European Journal of Public Health, 2021, 31, 1105-1107.	0.1	10

#	Article	IF	Citations
37	Chronic rhinosinusitis with nasal polyps is associated with impaired TMEM16A-mediated epithelial chloride secretion. Journal of Allergy and Clinical Immunology, 2021, 147, 2191-2201.e2.	1.5	9
38	Congenital Deletion of Nedd4-2 in Lung Epithelial Cells Causes Progressive Alveolitis and Pulmonary Fibrosis in Neonatal Mice. International Journal of Molecular Sciences, 2021, 22, 6146.	1.8	12
39	Effects of Lumacaftorâ€“Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis. Annals of the American Thoracic Society, 2021, 18, 971-980.	1.5	65
40	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1522-1532.	2.5	146
41	Magnetic Resonance Imaging Detects Progression of Lung Disease and Impact of Newborn Screening in Preschool Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 943-953.	2.5	41
42	Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. Journal of Clinical Investigation, 2021, 131, .	3.9	70
43	Linking Fibrotic Remodeling and Ultrastructural Alterations of Alveolar Epithelial Cells after Deletion of Nedd4-2. International Journal of Molecular Sciences, 2021, 22, 7607.	1.8	5
44	Triple Therapy for Cystic Fibrosis Phe508delâ€“Gating and â€“Residual Function Genotypes. New England Journal of Medicine, 2021, 385, 815-825.	13.9	140
45	Cross-reactive CD4 ⁺ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science, 2021, 374, eabh1823.	6.0	221
46	SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020. Eurosurveillance, 2021, 26, .	3.9	32
47	Maintenance of Elective Patient Care at Berlin University Children's Hospital During the COVID-19 Pandemic. Frontiers in Pediatrics, 2021, 9, 694963.	0.9	1
48	Increased Inflammatory Markers Detected in Nasal Lavage Correlate with Paranasal Sinus Abnormalities at MRI in Adolescent Patients with Cystic Fibrosis. Antioxidants, 2021, 10, 1412.	2.2	8
49	Prevalence of SARS-CoV-2 Infections Among Students, Teachers, and Household Members During Lockdown and Split Classes in Berlin, Germany. JAMA Network Open, 2021, 4, e2127168.	2.8	9
50	Self-collected oral, nasal and saliva samples yield sensitivity comparable to professionally collected oro-nasopharyngeal swabs in SARS-CoV-2 diagnosis among symptomatic outpatients. International Journal of Infectious Diseases, 2021, 110, 261-266.	1.5	15
51	Polyglycerolâ€Based Mucusâ€Inspired Hydrogels. Macromolecular Rapid Communications, 2021, 42, e2100303.	2.0	8
52	Relationship between airway dysbiosis, inflammation and lung function in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 754-760.	0.3	25
53	Analysis of Severe Acute Respiratory Syndrome 2 Replication in Explant Cultures of the Human Upper Respiratory Tract Reveals Broad Tissue Tropism of Wild-Type and B.1.1.7 Variant Viruses. Journal of Infectious Diseases, 2021, 224, 2020-2024.	1.9	5
54	Untimely TGFÎ² responses in COVID-19 limit antiviral functions of NK cells. Nature, 2021, 600, 295-301.	13.7	146

#	Article	IF	Citations
55	IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease. European Respiratory Journal, 2021, 57, 1900716.	3.1	14
56	Reply to: Contrast Enhanced Magnetic Resonance Imaging Does Not Detect a Progression in Lung Morphological Score in Preschool Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, , .	2.5	0
57	Visualization of Ectopic Serine Protease Activity by FÃ¶rster Resonance Energy Transfer-Based Reporters. ACS Chemical Biology, 2021, 16, 2174-2184.	1.6	1
58	Epigenetic reprogramming of airway macrophages promotes polarization and inflammation in muco-obstructive lung disease. Nature Communications, 2021, 12, 6520.	5.8	38
59	A Volatile and Dynamic Longitudinal Microbiome Is Associated With Less Reduction in Lung Function in Adolescents With Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 763121.	1.8	5
60	The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124.	5.2	573
61	Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 141-147.	2.5	43
62	Lack of IL-1 Receptor Signaling Reduces Spontaneous Airway Eosinophilia in Juvenile Mice with Muco-Obstructive Lung Disease. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 300-309.	1.4	7
63	Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1193-1208.	2.5	137
64	Comparison of Organoid Swelling and In Vivo Biomarkers of CFTR Function to Determine Effects of Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1589-1592.	2.5	23
65	Protease FRET Reporters Targeting Neutrophil Extracellular Traps. Journal of the American Chemical Society, 2020, 142, 20299-20305.	6.6	28
66	Geographical Accessibility of Pediatric Inpatient, Nephrology, and Urology Services in Europe. Frontiers in Pediatrics, 2020, 8, 395.	0.9	0
67	ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies. European Respiratory Journal, 2020, 56, 2000946.	3.1	33
68	Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases. ERJ Open Research, 2020, 6, 00408-2020.	1.1	18
69	Compromised<scp>DNA</scp>repair is responsible for diabetesâ€associated fibrosis. EMBO Journal, 2020, 39, e103477.	3.5	49
70	Normative data for multiple breath washout outcomes in school-aged Caucasian children. European Respiratory Journal, 2020, 55, 1901302.	3.1	79
71	CRISPRi-mediated functional analysis of lung disease-associated loci at non-coding regions. NAR Genomics and Bioinformatics, 2020, 2, lqaa036.	1.5	7
72	Geneâ€“Dose Effect of MEFV Gain-of-Function Mutations Determines ex vivo Neutrophil Activation in Familial Mediterranean Fever. Frontiers in Immunology, 2020, 11, 716.	2.2	23

#	Article	IF	Citations
73	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). Infection, 2020, 48, 619-626.	2.3	79
74	New method for rapid and dynamic quantification of elastase activity on sputum neutrophils from patients with cystic fibrosis using flow cytometry. European Respiratory Journal, 2020, 55, 1902355.	3.1	4
75	Magnetic Resonance Imaging Detects Chronic Rhinosinusitis in Infants and Preschool Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2020, 17, 714-723.	1.5	23
76	The value of chest magnetic resonance imaging compared to chest radiographs with and without additional lung ultrasound in children with complicated pneumonia. PLoS ONE, 2020, 15, e0230252.	1.1	18
77	Rhinovirus Infection Is Associated With Airway Epithelial Cell Necrosis and Inflammation via Interleukin-1 in Young Children With Cystic Fibrosis. Frontiers in Immunology, 2020, 11, 596.	2.2	16
78	Pseudomonas aeruginosa Modulates the Antiviral Response of Bronchial Epithelial Cells. Frontiers in Immunology, 2020, 11, 96.	2.2	16
79	Echo Timeâ€Dependence of Observed Lung <scp>T₁</scp> in Patients With Cystic Fibrosis and Correlation With Clinical Metrics. Journal of Magnetic Resonance Imaging, 2020, 52, 1645-1654.	1.9	17
80	Neutrophil Adaptations upon Recruitment to the Lung: New Concepts and Implications for Homeostasis and Disease. International Journal of Molecular Sciences, 2020, 21, 851.	1.8	67
81	At the forefront of cystic fibrosis Basic Science research: 16th ECFS Basic Science Conference. Journal of Cystic Fibrosis, 2020, 19, 169-170.	0.3	1
82	CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank. Cell Stem Cell, 2020, 26, 503-510.e7.	5.2	136
83	Intravital microscopic optical coherence tomography imaging to assess mucus-mobilizing interventions for muco-obstructive lung disease in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L518-L524.	1.3	11
84	Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice. Nature Communications, 2020, 11, 2012.	5.8	52
85	SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature, 2020, 587, 270-274.	13.7	1,115
86	Lack of Kcnn4 improves mucociliary clearance in muco-obstructive lung disease. JCI Insight, 2020, 5, .	2.3	11
87	Elexacaftorâ€“Tezacaftorâ€“Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New England Journal of Medicine, 2019, 381, 1809-1819.	13.9	1,231
88	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet, The, 2019, 394, 1940-1948.	6.3	804
89	Targeting of cathepsin S reduces cystic fibrosis-like lung disease. European Respiratory Journal, 2019, 53, 1801523.	3.1	31
90	Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Research, 2019, 5, 00082-2019.	1.1	72

#	Article	IF	Citations
91	Ten years of chest MRI for patients with cystic fibrosis. Der Radiologe, 2019, 59, 10-20.	1.7	14
92	Midterm Reproducibility of Chest Magnetic Resonance Imaging in Adults with Clinically Stable Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 103-107.	2.5	25
93	Cathepsin G Activity as a New Marker for Detecting Airway Inflammation by Microscopy and Flow Cytometry. ACS Central Science, 2019, 5, 539-548.	5.3	21
94	Authors' response: Letter to the Editor â€˜Comparison of lung clearance index determined by washout of N2 and SF6 in infants and preschool children with cystic fibrosisâ€™. Journal of Cystic Fibrosis, 2019, 18, e28-e29.	0.3	0
95	Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the ILâ€1 signaling pathway. Pediatric Pulmonology, 2019, 54, S5-S12.	1.0	48
96	Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany. Pediatric Infectious Disease Journal, 2019, 38, e295-e300.	1.1	7
97	Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1238-1248.	2.5	96
98	Comparison of lung clearance index determined by washout of N2 and SF6 in infants and preschool children with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 399-406.	0.3	21
99	Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 536-542.	0.3	41
100	Assessment of Suspected Vascular Rings and Slings and/or Airway Pathologies Using Magnetic Resonance Imaging Rather Than Computed Tomography. Respiration, 2019, 97, 108-118.	1.2	4
101	Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 873-881.	2.5	68
102	Progression of lung disease detected by MRI and impact of NBS in preschool children with cystic fibrosis. , 2019, , .		1
103	Lung disease phenotypes caused by over-expression of combinations of alpha, beta, and gamma subunits of the epithelial sodium channel in mouse airways. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, ajplung.00382.2.	1.3	10
104	Non-contrast enhanced magnetic resonance imaging detects mosaic signal intensity in early cystic fibrosis lung disease. European Journal of Radiology, 2018, 101, 178-183.	1.2	26
105	One time quantitative PCR detection of Pseudomonas aeruginosa to discriminate intermittent from chronic infection in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 348-355.	0.3	29
106	Effects of Lumacaftorâ€“Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1433-1442.	2.5	95
107	Mucopurulent Triggering of the Airway Epithelium. Implications in Health and Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 418-420.	2.5	3
108	Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis. European Respiratory Journal, 2018, 51, 1701910.	3.1	67

#	Article	IF	Citations
109	Three-center feasibility of lung clearance index in infants and preschool children with cystic fibrosis and other lung diseases. Journal of Cystic Fibrosis, 2018, 17, 249-255.	0.3	33
110	Cystic fibrosis research topics featured at the 14th ECFS Basic Science Conference: Chairman's summary. Journal of Cystic Fibrosis, 2018, 17, S1-S4.	0.3	5
111	Reply to Verbanck and Vanderhelst: The Respective Roles of Lung Clearance Index and Magnetic Resonance Imaging in the Clinical Management of Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 410-411.	2.5	1
112	Emerging Concepts and Therapies for Mucoobstructive Lung Disease. Annals of the American Thoracic Society, 2018, 15, S216-S226.	1.5	37
113	Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis. Frontiers in Pharmacology, 2018, 9, 1112.	1.6	32
114	VX-659â€“Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. New England Journal of Medicine, 2018, 379, 1599-1611.	13.9	280
115	VX-445â€“Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. New England Journal of Medicine, 2018, 379, 1612-1620.	13.9	509
116	Multicentre standardisation of chest MRI as radiation-free outcome measure of lung disease in young children with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 518-527.	0.3	68
117	Ductal Mucus Obstruction and Reduced Fluid Secretion Are Early Defects in Chronic Pancreatitis. Frontiers in Physiology, 2018, 9, 632.	1.3	13
118	Expression and function of Anoctamin 1/TMEM16A calcium-activated chloride channels in airways of in vivo mouse models for cystic fibrosis research. Pflugers Archiv European Journal of Physiology, 2018, 470, 1335-1348.	1.3	12
119	Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 715-722.	0.3	47
120	Ion Channel Modulators in Cystic Fibrosis. Chest, 2018, 154, 383-393.	0.4	128
121	Validation of automated lobe segmentation on paired inspiratory-expiratory chest CT in 8-14 year-old children with cystic fibrosis. PLoS ONE, 2018, 13, e0194557.	1.1	25
122	Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 349-359.	2.5	169
123	MRI accelerating progress in functional assessment of cystic fibrosis lung disease. Journal of Cystic Fibrosis, 2017, 16, 165-167.	0.3	12
124	Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies. European Respiratory Journal, 2017, 49, 1600903.	3.1	90
125	Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. Cell and Tissue Research, 2017, 367, 537-550.	1.5	128
126	Rare cause for hemoptysis in an adolescent: Bronchial capillary hemangioma. Pediatric Pulmonology, 2017, 52, E40-E42.	1.0	3

#	Article	IF	Citations
127	Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Molecular Medicine, 2017, 9, 462-481.	3.3	79
128	Protean proteases: at the cutting edgeÂofÂlung diseases. European Respiratory Journal, 2017, 49, 1501200.	3.1	49
129	Disruption of the Hepcidin/Ferroportin Regulatory System Causes Pulmonary Iron Overload and Restrictive Lung Disease. EBioMedicine, 2017, 20, 230-239.	2.7	45
130	Dephasing and diffusion on the alveolar surface. Physical Review E, 2017, 95, 022415.	0.8	13
131	Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport. Current Opinion in Pharmacology, 2017, 34, 91-97.	1.7	58
132	Homeostatic nuclear RAGEâ€“ATM interaction is essential for efficient DNA repair. Nucleic Acids Research, 2017, 45, 10595-10613.	6.5	66
133	Cellular distribution and function of ion channels involved in transport processes in rat tracheal epithelium. Physiological Reports, 2017, 5, e13290.	0.7	13
134	Impaired mucus clearance exacerbates allergen-induced type 2 airway inflammation in juvenile mice. Journal of Allergy and Clinical Immunology, 2017, 140, 190-203.e5.	1.5	17
135	An informative intragenic microsatellite marker suggests the IL-1 receptor as a genetic modifier in cystic fibrosis. European Respiratory Journal, 2017, 50, 1700426.	3.1	8
136	Comparison of Oropharyngeal Microbiota from Children with Asthma and Cystic Fibrosis. Mediators of Inflammation, 2017, 2017, 1-10.	1.4	32
137	Chronic but not intermittent infection withPseudomonas aeruginosais associated with global changes of the lung microbiome in cystic fibrosis. European Respiratory Journal, 2017, 50, 1701086.	3.1	33
138	Early detection and sensitive monitoring of CF lung disease: Prospects of improved and safer imaging. Pediatric Pulmonology, 2016, 51, S49-S60.	1.0	44
139	Cigarette smoke causes acute airway disease and exacerbates chronic obstructive lung disease in neonatal mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L602-L610.	1.3	22
140	Quantification of heterogeneity in lung disease with image-based pulmonary function testing. Scientific Reports, 2016, 6, 29438.	1.6	50
141	Mukoviszidose. , 2016, , 303-312.		0
142	Imaging of Cystic Fibrosis Lung Disease and Clinical Interpretation. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2016, 188, 834-845.	0.7	77
143	A product of immunoreactive trypsinogen and pancreatitis-associated protein as second-tier strategy in cystic fibrosis newborn screening. Journal of Cystic Fibrosis, 2016, 15, 752-758.	0.3	14
144	Neutrophil elastase and matrix metalloproteinase 12 in cystic fibrosis lung disease. Molecular and Cellular Pediatrics, 2016, 3, 25.	1.0	37

#	Article	IF	Citations
145	A Protease Inhibitor Tackles Epithelial Sodium Channels in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 650-652.	2.5	1
146	Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl^{â^'} channels. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L593-L602.	1.3	36
147	Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 2813-2821.	1.4	30
148	Optical coherence tomography detects structural abnormalitiesof the nasal mucosa in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 216-222.	0.3	19
149	Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2016, 13 Suppl 2, S177-85.	1.5	41
150	Finding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25â€“28 March 2015. Journal of Cystic Fibrosis, 2015, 14, 700-705.	0.3	2
151	Imaging modalities in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 609-616.	1.2	34
152	Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. Pediatric Pulmonology, 2015, 50, 655-664.	1.0	62
153	Free DNA in Cystic Fibrosis Airway Fluids Correlates with Airflow Obstruction. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	100
154	Airway Surface Dehydration Aggravates Cigarette Smoke-Induced Hallmarks of COPD in Mice. PLoS ONE, 2015, 10, e0129897.	1.1	21
155	Comparison of Microbiomes from Different Niches of Upper and Lower Airways in Children and Adolescents with Cystic Fibrosis. PLoS ONE, 2015, 10, e0116029.	1.1	133
156	Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registryâ€”The EXCITING-ILD Registry. BioMed Research International, 2015, 2015, 1-9.	0.9	42
157	Supplementation with Red Palm Oil IncreasesÎ²-Carotene and Vitamin A Blood Levels in Patients with Cystic Fibrosis. Mediators of Inflammation, 2015, 2015, 1-7.	1.4	10
158	New Developments in Cystic Fibrosis Airway Inflammation. Mediators of Inflammation, 2015, 2015, 1-2.	1.4	6
159	Genetic Deletion and Pharmacological Inhibition of PI3KÎ³Reduces Neutrophilic Airway Inflammation and Lung Damage in Mice with Cystic Fibrosis-Like Lung Disease. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	13
160	miRNA-221 is elevated in cystic fibrosis airway epithelial cells and regulates expression of ATF6. Molecular and Cellular Pediatrics, 2015, 2, 1.	1.0	27
161	miR-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production. European Respiratory Journal, 2015, 46, 1350-1360.	3.1	64
162	Targeting ion channels in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 561-570.	0.3	126

#	Article	IF	Citations
163	Niemann-Pick Type C-2 Disease: Identification by Analysis of Plasma Cholestane-3Î²,5Î±,6Î²-Triol and Further Insight into the Clinical Phenotype. JIMD Reports, 2015, 23, 17-26.	0.7	35
164	The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cellâ€“derived leukocyte elastase. Nature Medicine, 2015, 21, 518-523.	15.2	182
165	Regulatory T-Cell Impairment in Cystic Fibrosis Patients with Chronic Pseudomonas Infection. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 914-923.	2.5	77
166	The role of chitin, chitinases, and chitinase-like proteins in pediatric lung diseases. Molecular and Cellular Pediatrics, 2015, 2, 3.	1.0	52
167	Hypoxic Epithelial Necrosis Triggers Neutrophilic Inflammation via IL-1 Receptor Signaling in Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 902-913.	2.5	78
168	Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1252-1255.	2.5	59
169	Bronchoalveolar Sublineage Specification of Pluripotent Stem Cells: Effect of Dexamethasone Plus cAMP-Elevating Agents and Keratinocyte Growth Factor. Tissue Engineering - Part A, 2015, 21, 669-682.	1.6	7
170	Lung arginase expression and activity is increased in cystic fibrosis mouse models. Journal of Applied Physiology, 2014, 117, 284-288.	1.2	11
171	Airway Mucus Obstruction Triggers Macrophage Activation and Matrix Metalloproteinase 12â€“Dependent Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 709-720.	1.4	76
172	A New Player in the Game: Epithelial Cathepsin S in Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 126-127.	2.5	10
173	Multiple Breath Washout Is Feasible in the Clinical Setting and Detects Abnormal Lung Function in Infants and Young Children with Cystic Fibrosis. Respiration, 2014, 87, 357-363.	1.2	48
174	Lack of Neutrophil Elastase Reduces Inflammation, Mucus Hypersecretion, and Emphysema, but Not Mucus Obstruction, in Mice with Cystic Fibrosisâ€“like Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1082-1092.	2.5	116
175	Early cystic fibrosis lung disease: Role of airway surface dehydration and lessons from preventive rehydration therapies in mice. International Journal of Biochemistry and Cell Biology, 2014, 52, 174-179.	1.2	28
176	Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. Journal of Cystic Fibrosis, 2014, 13, 15-23.	0.3	39
177	Chronic ivacaftor treatment: Getting F508del-CFTR into more trouble?. Journal of Cystic Fibrosis, 2014, 13, 605-607.	0.3	8
178	New metrics for translational research. Lancet Respiratory Medicine,the, 2014, 2, e13-e14.	5.2	4
179	Nanoparticle uptake by airway phagocytes after fungal spore challenge in murine allergic asthma and chronic bronchitis. BMC Pulmonary Medicine, 2014, 14, 116.	0.8	14
180	CFTR: cystic fibrosis and beyond. European Respiratory Journal, 2014, 44, 1042-1054.	3.1	207

#	Article	IF	Citations
181	Magnetic Resonance Imaging Detects Changes in Structure and Perfusion, and Response to Therapy in Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 956-965.	2.5	228
182	FRETâ€based and other fluorescent proteinase probes. Biotechnology Journal, 2014, 9, 266-281.	1.8	46
183	CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy. Journal of Cystic Fibrosis, 2014, 13, 363-372.	0.3	34
184	Pathophysiology of cystic fibrosis lung disease. , 2014, , 1-13.		5
185	Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Particle and Fibre Toxicology, 2013, 10, 19.	2.8	74
186	Computerized image analysis of iron-stained macrophages. Annals of Hematology, 2013, 92, 1195-1199.	0.8	3
187	Keratinocyte Growth Factor and Dexamethasone Plus Elevated cAMP Levels Synergistically Support Pluripotent Stem Cell Differentiation into Alveolar Epithelial Type II Cells. Tissue Engineering - Part A, 2013, 19, 938-951.	1.6	23
188	Validation of Fourier decomposition MRI with dynamic contrast-enhanced MRI using visual and automated scoring of pulmonary perfusion in young cystic fibrosis patients. European Journal of Radiology, 2013, 82, 2371-2377.	1.2	99
189	Hypertonic Saline Is Effective in the Prevention and Treatment of Mucus Obstruction, but Not Airway Inflammation, in Mice with Chronic Obstructive Lung Disease. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 410-417.	1.4	45
190	Automatic Airway Analysis on Multidetector Computed Tomography in Cystic Fibrosis. Journal of Thoracic Imaging, 2013, 28, 104-113.	0.8	66
191	Pulmonary Emphysema in Cystic Fibrosis Detected by Densitometry on Chest Multidetector Computed Tomography. PLoS ONE, 2013, 8, e73142.	1.1	40
192	mCLCA3 Does Not Contribute to Calcium-Activated Chloride Conductance in Murine Airways. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 87-93.	1.4	22
193	Morphologic and functional scoring of cystic fibrosis lung disease using MRI. European Journal of Radiology, 2012, 81, 1321-1329.	1.2	163
194	BPIFB1 (LPLUNC1) is upregulated in cystic fibrosis lung disease. Histochemistry and Cell Biology, 2012, 138, 749-758.	0.8	31
195	Hfe Deficiency Impairs Pulmonary Neutrophil Recruitment in Response to Inflammation. PLoS ONE, 2012, 7, e39363.	1.1	14
196	CFTR Regulates Early Pathogenesis of Chronic Obstructive Lung Disease in Î²ENaC-Overexpressing Mice. PLoS ONE, 2012, 7, e44059.	1.1	44
197	Spatially Resolved Monitoring of Neutrophil Elastase Activity with Ratiometric Fluorescent Reporters. Angewandte Chemie - International Edition, 2012, 51, 6258-6261.	7.2	75
198	Homozygous CFTR mutation M348K in a boy with respiratory symptoms and failure to thrive. Disease-causing mutation or benign alteration?. European Journal of Pediatrics, 2012, 171, 1039-1046.	1.3	4

#	Article	IF	Citations
199	SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. Journal of Clinical Investigation, 2012, 122, 3629-3634.	3.9	83
200	Pharmacological therapy for cystic fibrosis: From bench to bedside. Journal of Cystic Fibrosis, 2011, 10, S129-S145.	0.3	58
201	The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. Journal of Cystic Fibrosis, 2011, 10, S172-S182.	0.3	133
202	The role of matrix metalloproteinases in cystic fibrosis lung disease. European Respiratory Journal, 2011, 38, 721-727.	3.1	93
203	The K+ Channel Opener 1-EBIO Potentiates Residual Function of Mutant CFTR in Rectal Biopsies from Cystic Fibrosis Patients. PLoS ONE, 2011, 6, e24445.	1.1	43
204	Use of a New-Generation Reverse Tetracycline Transactivator System for Quantitative Control of Conditional Gene Expression in the Murine Lung. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 244-254.	1.4	28
205	In vivo monitoring of cystic fibrosis-like lung disease in mice by volumetric computed tomography. European Respiratory Journal, 2011, 38, 1060-1070.	3.1	48
206	The Chitinase-Like Protein YKL-40 Modulates Cystic Fibrosis Lung Disease. PLoS ONE, 2011, 6, e24399.	1.1	44
207	Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitisâ€associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. Journal of Inherited Metabolic Disease, 2010, 33, 263-271.	1.7	39
208	CXCR2 mediates NADPH oxidaseâ€“independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nature Medicine, 2010, 16, 1018-1023.	15.2	189
209	Allergic airway inflammation induces a pro-secretory epithelial ion transport phenotype in mice. European Respiratory Journal, 2010, 36, 1436-1447.	3.1	55
210	Airway Surface Liquid Volume Regulation Determines Different Airway Phenotypes in Liddle Compared with Î²ENaC-overexpressing Mice. Journal of Biological Chemistry, 2010, 285, 26945-26955.	1.6	61
211	Reporters to monitor cellular MMP12 activity. Proceedings of SPIE, 2010, , .	0.8	2
212	Airway and Lung Pathology Due to Mucosal Surface Dehydration in Î²-Epithelial Na+ Channel-Overexpressing Mice: Role of TNF-Î± and IL-4RÎ± Signaling, Influence of Neonatal Development, and Limited Efficacy of Glucocorticoid Treatment. Journal of Immunology, 2009, 182, 4357-4367.	0.4	86
213	Role of the amilorideâ€sensitive epithelial Na⁺ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease. Experimental Physiology, 2009, 94, 171-174.	0.9	50
214	Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation. Nature Chemical Biology, 2009, 5, 628-630.	3.9	97
215	Chediak-Steinbrinck-Higashi Syndrome. , 2009, , 314-314.		0
216	Role of Cilia, Mucus, and Airway Surface Liquid in Mucociliary Dysfunction: Lessons from Mouse Models. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 13-24.	0.7	165

#	Article	IF	Citations
217	Preventive but Not Late Amiloride Therapy Reduces Morbidity and Mortality of Lung Disease in Î²ENaC-overexpressing Mice. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1245-1256.	2.5	109
218	Development of Chronic Bronchitis and Emphysema in Î²-Epithelial Na⁺ Channelâ€“Overexpressing Mice. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 730-742.	2.5	170
219	Modelling Dysregulated Na⁺ Absorption in Airway Epithelial Cells with Mucosal Nystatin Treatment. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 423-434.	1.4	16
220	Role of Cilia, Mucus, and Airway Surface Liquid in Mucociliary Dysfunction: Lessons from Mouse Models. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	1
221	Signaling pathways regulating the airway phenotype of mice exhibiting airway surface dehydration. FASEB Journal, 2008, 22, 328.7.	0.2	0
222	Correction of the CF defect by curcumin: hypes and disappointments. BioEssays, 2005, 27, 9-13.	1.2	45
223	Pathogenesis of Pulmonary Disease in Cystic Fibrosis. , 2005, 34, 116-121.		6
224	Characterization of Wild-Type and Î”F508 Cystic Fibrosis Transmembrane Regulator in Human Respiratory Epithelia. Molecular Biology of the Cell, 2005, 16, 2154-2167.	0.9	235
225	Control of ion transport in mammalian airways by protease activated receptors type 2 (PARâ€2). FASEB Journal, 2005, 19, 969-970.	0.2	40
226	Role of CFTR and Other Ion Channels in Cystic Fibrosis. , 2005, , 23-41.		0
227	Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nature Medicine, 2004, 10, 487-493.	15.2	817
228	The Î”F508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology, 2004, 126, 32-41.	0.6	95
229	CFTR Clâ^' channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology, 2004, 127, 1085-1095.	0.6	130
230	Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. Journal of Cystic Fibrosis, 2004, 3, 165-169.	0.3	69
231	Pharmacotherapy of the Ion Transport Defect in Cystic Fibrosis. Treatments in Respiratory Medicine, 2003, 2, 299-309.	1.4	52
232	Transcript analysis of the cystic fibrosis splicing mutation 1525-1G>A shows use of multiple alternative splicing sites and suggests a putative role of exonic splicing enhancers. Journal of Medical Genetics, 2003, 40, 88e-88.	1.5	37
233	Modulation of Ca2+-Activated Clâ^' Secretion by Basolateral K+ Channels in Human Normal and Cystic Fibrosis Airway Epithelia. Pediatric Research, 2003, 53, 608-618.	1.1	101
234	Electrolyte Transport in the Mammalian Colon: Mechanisms and Implications for Disease. Physiological Reviews, 2002, 82, 245-289.	13.1	582

#	Article	IF	Citations
235	Activation of ion secretion via proteinase-activated receptor-2 in human colon. American Journal of Physiology - Renal Physiology, 2002, 282, G200-G210.	1.6	58
236	Ion Transport Induced by Proteinase-Activated Receptors (PAR2) in Colon and Airways. Cell Biochemistry and Biophysics, 2002, 36, 209-214.	0.9	43
237	Pharmacotherapy Of The Ion Transport Defect In Cystic Fibrosis. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 857-867.	0.9	29
238	The cystic fibrosis transmembrane conductance regulator (CFTR) inhibits ENaC through an increase in the intracellular Clâ^'concentration. EMBO Reports, 2001, 2, 1047-1051.	2.0	84
239	A novel missense mutation, S1159F, in exon 19 of the CFTR gene. , 2000, 15, 390-390.		0
240	A novel frameshift mutation, c.1870delG, in exon 12 of the CFTR gene. Human Mutation, 2000, 16, 277-277.	1.1	0
241	Effect of genistein on native epithelial tissue from normal individuals and CF patients and on ion channels expressed in Xenopus oocytes. British Journal of Pharmacology, 2000, 130, 1884-1892.	2.7	36
242	Control of epithelial Na+ conductance by the cystic fibrosis transmembrane conductance regulator. Pflugers Archiv European Journal of Physiology, 2000, 440, 193-201.	1.3	55
243	Inhibition of Amiloride-Sensitive Epithelial Na+Absorption by Extracellular Nucleotides in Human Normal and Cystic Fibrosis Airways. American Journal of Respiratory Cell and Molecular Biology, 2000, 23, 755-761.	1.4	96
244	Role of K_VLQT1 in Cyclic Adenosine Monophosphateâ€"Mediated Cl^{â^'} Secretion in Human Airway Epithelia. American Journal of Respiratory Cell and Molecular Biology, 2000, 23, 283-289.	1.4	93
245	Cystic Fibrosis Transmembrane Conductance Regulator Inhibits Epithelial Na+ Channels Carrying Liddle's Syndrome Mutations. Journal of Biological Chemistry, 1999, 274, 13894-13899.	1.6	39
246	The first-nucleotide binding domain of the cystic-fibrosis transmembrane conductance regulator is important for inhibition of the epithelial Na+ channel. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5310-5315.	3.3	88
247	The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways.. Journal of Clinical Investigation, 1998, 102, 15-21.	3.9	191
248	The cystic fibrosis transmembrane conductance regulator attenuates the endogenous Ca 2+ activated Cl - conductance of Xenopus oocytes. Pflugers Archiv European Journal of Physiology, 1997, 435, 178-181.	1.3	63
249	Wild type but not Î"F508 CFTR inhibits Na+ conductance when coexpressed in Xenopus oocytes. FEBS Letters, 1996, 381, 47-52.	1.3	142
250	cAMP Stimulation of CFTR-expressing Xenopus oocytes activates a chromanol-inhibitable K+ conductance. Pflugers Archiv European Journal of Physiology, 1996, 432, 516-522.	1.3	43
251	Mutations in the putative pore-forming domain of CFTR do not change anion selectivity of the cAMP activated Clâ^'conductance. FEBS Letters, 1995, 374, 312-316.	1.3	46